Arrow Mark Colorado Holdings LLC Inhibrx, Inc. Transaction History

Arrow Mark Colorado Holdings LLC

$7.59 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$32.76 - $39.56 $2.15 Million - $2.6 Million	-65,661 Reduced 6.86%	891,220 $31.2 Million
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $28,985 - $75,962	-1,999 Reduced 0.21%	956,881 $36.4 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $296,070 - $485,653	17,457 Added 1.85%	958,880 $24.9 Million
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $3.65 Million - $5.37 Million	-197,914 Reduced 17.37%	941,423 $17.8 Million
Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $4.03 Million - $6.66 Million	-199,690 Reduced 14.91%	1,139,337 $28.1 Million
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $847,760 - $1.81 Million	-73,209 Reduced 5.18%	1,339,027 $24 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $1.05 Million - $3.1 Million	122,763 Added 9.52%	1,412,236 $16 Million
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $431,871 - $937,567	21,713 Added 1.71%	1,289,473 $28.7 Million
Q4 2021 Feb 14, 2022	SELL	$26.75 - $46.02 $3.15 Million - $5.42 Million	-117,882 Reduced 8.51%	1,267,760 $55.4 Million
Q3 2021 Nov 15, 2021	SELL	$25.18 - $37.81 $1.49 Million - $2.24 Million	-59,188 Reduced 4.1%	1,385,642 $46.2 Million
Q2 2021 Aug 16, 2021	SELL	$14.69 - $27.52 $1.29 Million - $2.42 Million	-87,957 Reduced 5.74%	1,444,830 $39.8 Million
Q1 2021 May 17, 2021	SELL	$16.27 - $41.26 $382,865 - $970,930	-23,532 Reduced 1.51%	1,532,787 $30.8 Million
Q4 2020 Feb 16, 2021	BUY	$15.96 - $50.0 $16.9 Million - $52.8 Million	1,056,593 Added 211.43%	1,556,319 $51.3 Million
Q3 2020 Nov 16, 2020	BUY	$16.77 - $20.65 $8.38 Million - $10.3 Million	499,726 New	499,726 $9 Million

Others Institutions Holding INBX

# of Institutions

Shares Held

25.3K

Call Options Held

Put Options Held

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

News

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.

Account